Product Description: Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
Applications: COVID-19-immunoregulation
Formula: C22H22Cl4N4O
Citations: Cancers (Basel). 2021 Jan 18;13(2):330./Neuroscience. 2019 Feb 19. pii: S0306-4522(19)30117-4. /Autophagy. 2021 Nov;17(11):3592-3606./Cell. 2019 Jan 24;176(3):636-648.e13. /Int J Mol Sci. 2024 May 3;25(9):5012./Structure. 2022 Aug 7;S0969-2126(22)00278-7.
References: [1]Seely KA, et al. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):905-15./[2]Zhang B, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019 Jan 24;176(3):636-648.e13./[3]Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268.
CAS Number: 158681-13-1
Molecular Weight: 500.25
Compound Purity: 99.95
Research Area: Cancer; Infection; Metabolic Disease
Solubility: DMSO : 33.33 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Bacterial;Cannabinoid Receptor
Deutsch
English
